login
  Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

Symplicity Renal Denervation System receives Health Canada licence


Wednesday, 18 Apr 2012 15:07
Renal denervation
Renal denervation

Medtronic  has announced that it has received a Health Canada licence for its Symplicity Renal Denervation System to reduce treatment-resistant high blood pressure in patients unresponsive to three or more anti-hypertensive medications. 


“Decreasing a patient’s systolic blood pressure from 160 to 130 mm Hg over a period of six months, which renal denervation has been shown to do, could prevent many heart attacks and strokes from ever happening,” said Barry Rubin, medical director, Peter Munk Cardiac Centre, Toronto, Ontario. “Our multidisciplinary renal denervation programme, which includes interventional radiologists, vascular surgeons, cardiologists, hypertension and kidney specialists will treat many eligible patients in the months ahead.”

Results from the SYMPLICITY HTN-1 trial have shown sustained safety and effectiveness of renal denervation with the system out to three years, and results from the SYMPLICITY HTN-2 trial showed safe, and statistically significant reduction of blood pressure (-33 mg Hg systolic blood pressure) at six months following the procedure and sustained to 12 months. These data were recently presented at the annual American College of Cardiology during an oral session, which was dedicated to renal denervation.


In addition to the licence from Health Canada, the Symplicity Renal Denervation System has received CE mark and a listing with Australia’s Therapeutic Goods Administration (TGA). The Symplicity Renal Denervation System is under investigational use in the United States.


About the Symplicity Renal Denervation System


The Symplicity Renal Denervation System accomplishes renal denervation via a minimally invasive procedure that disables sympathetic nerves located in the renal artery walls, which has been shown to reduce high blood pressure. The system consists of a generator and a flexible catheter. The catheter is introduced through the femoral artery in the upper thigh and is threaded up into the renal artery near each kidney. Once in place, the tip of the catheter delivers low-power radiofrequency energy according to a proprietary algorithm, or pattern, to ablate the surrounding sympathetic nerves. The procedure does not involve a permanent implant.




Add New Comment

Related Items


Most popular


Combined mitral valve repair and CABG do not provide additional benefits
Friday, 28 Nov 2014
The combination of coronary artery bypass grafting (CABG) and mitral valve repair is not associated with additional benefits compared with CABG alone in patients with multivessel disease and moderate ... Combined mitral valve repair and CABG do not provide additional benefits

REVA implants first patients with Fantom scaffold
Thursday, 04 Dec 2014
REVA Medical has initiated patient enrollment with its Fantom bioresorbable drug-eluting scaffold. REVA implants first patients with Fantom scaffold

Too early to say that renal denervation is a failed therapy
Thursday, 04 Dec 2014
In a new consensus statement, the Joint UK Societies claim that the negative results of SYMPLICITY HTN-3 should not be used as a “rationale for abandoning” renal denervation as a “novel therapeutic ... Too early to say that renal denervation is a failed therapy

Features


ICI meeting is a “fruitful ground for new developments” in interventional cardiology
Tuesday, 13 Jan 2015
Rafael Bayer, co-chairman of the Innovation in Cardiovascular Intervention (ICI) meeting (14–16 December 2014, Tel Aviv, Israel), speaks to Cardiovascular News about the event’s unique features. ICI meeting is a “fruitful ground for new developments” in interventional cardiology

Performing TAVI in a hybrid operating room
Wednesday, 10 Dec 2014
Daniel O’ Hair believes hybrid ORs may provide distinct advantages for complex TAVI cases. He speaks to Cardiovascular News about his experience of performing TAVI in a hybrid OR. Performing TAVI in a hybrid operating room

Profiles


Sunil Rao
Thursday, 23 Oct 2014
Sunil Rao speaks to Cardiovascular News about his career highlights, including his research into ... Sunil Rao

Azeem Latib
Wednesday, 24 Sep 2014
Azeem Latib (senior interventional cardiologist, San Raffaele Hospital and EMO-GVM Centro Cuore C... Azeem Latib

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions